Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis - current experience
2021
Abstract
Multiple sclerosis (MS) is a chronic inflammatory autoimmune an d neurodegenerative disease of the central nervous system affecting most commonly young adults. Secondary-progressive MS (SP-MS) is the second most common form of MS.
While there are many disease-modifying drugs indicated for relapsing-remitting MS (RR-MS), effective treatment for SP-MS was lacking. Siponimod, a selective modulator of sfingosin-1-phosphate receptors, is the first oral drug to treat SP-MS, that showed a statistically significant decrease in disabilitiy progression.
Its efficacy was demonstrated in the EXPAND trial.